Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
Despite this, Olumiant is anticipated to maintain a substantial lead over Litfulo in the market.
- Despite this, Olumiant is anticipated to maintain a substantial lead over Litfulo in the market.
- Prescribers of both brands express high and comparable satisfaction levels, far surpassing the satisfaction rates associated with non-advanced systemic treatment options.
- Recent data from Spherix's published studies highlight minimal differentiation among prescribers regarding the two JAK inhibitors.
- Furthermore, barriers preventing increased use of either JAK inhibitor remain closely contested, with safety concerns topping the list for each asset.